INS and Hyperglycemia: Velagliflozin increased insulin sensitivity in 6 nondiabetic insulin‐resistant obese cats [10] and, in diabetic cats, improved clinical signs and hyperglycemia similarly to lente insulin [7] and effectively normalized glycemia and fructosamine concentration in 127 out of 157 (81%) cats, which completed a 6‐month baseline‐controlled, open‐label clinical field trial [6].